"Northwest Biotherapeutics Submits Marketing Application for DCVax®-L to UK MHRA for Glioblastoma Treatment"

Northwest Biotherapeutics has submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for DCVax-L, a personalized immune therapy for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma. The company believes that DCVax-L can offer a new treatment option for GBM patients and aims to bring the treatment to as many patients as possible. GBM is the most lethal and common form of primary brain cancer, and current treatment options have not significantly improved patient survival in decades.